Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG1511 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | po bid |
| RG1511 | DRUG | Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid. |
Inclusion Criteria: * adult patients, 18-65 years of age; * type 2 diabetic patients; * naive to anti-diabetic therapy, or taken off current anti-diabetic therapy for \>=2 weeks before first treatment. Exclusion Criteria: * type 1 diabetes mellitus; * clinically significant cardiovascular disease...
RG1511 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and has completed one trial in patients with this condition.
RG1511 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus.
RG1511 is in Phase 1 clinical development. It has completed one Phase 1 trial, and the drug remains investigational, meaning it has not yet been approved for any use.
RG1511 has one completed clinical trial, NCT00517465, titled 'A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.' This Phase 1 study enrolled 41 participants and was conducted in Germany, Hungary, Slovakia, and the United Kingdom.
Yes, RG1511 is also referred to as R1511 in clinical trial documentation. The completed study NCT00517465 uses the name R1511, indicating that both names refer to the same investigational drug.